Full-Time
Medical Director
Posted on 10/31/2025
ArteraAI
51-200 employees
Delivers CLIA-certified multi-modal prostate cancer test
Compensation Overview
$250k - $285k/yr
Remote in USA
Remote
Travel up to 50% nationally.
 Medical, Clinical & Veterinary (1) |
|---|
- M.D. degree with completed residency and fellowship training in Urology, Radiation Oncology, or Medical Oncology.
- Board-certified (or previously board-certified) and experience in managing prostate cancer patients.
- Demonstrated expertise in GU oncology with a strong peer reputation in the field.
- Excellent communication and presentation skills with the ability to connect peer-to-peer with practicing physicians.
- Ability to travel up to 50% nationally.
- Clinical Engagement & Education: Serve as a medical affairs field resource for Artera’s GU tests, providing peer-to-peer education to practicing clinicians and demonstrating how the test can be put in context of their clinical needs.
- Act as a peer advisor and trusted partner to clinicians integrating Artera’s tests into practice.
- Build and maintain strong relationships with key opinion leaders and practicing GU clinicians.
- Deliver scientific presentations at medical group meetings, academic centers, and tumor boards.
- Lead speaker programs, advisory boards, and other educational initiatives.
- Medical Support for Commercial Activities: Collaborate with commercial colleagues to support responsible and compliant customer engagements.
- Provide expert input into training for sales and market access teams.
- Support responses to complex clinical inquiries from customers and field partners.
- Field Insights & Feedback: Collect and synthesize feedback from the field regarding clinical utility, unmet needs, and barriers to adoption.
- Communicate insights to Medical Affairs and cross-functional stakeholders to inform product strategy, evidence generation, and education efforts
- Prior experience in industry Medical Affairs or clinical trial leadership.
- Established relationships with GU oncology networks and professional societies.
- Experience serving as a speaker, advisor, or investigator in clinical research.
ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.
Company Size
51-200
Company Stage
Early VC
Total Funding
$175M
Headquarters
Menlo Park, California
Founded
2021
Simplify's Take
What believers are saying
- Tempus partnership accesses 50% of US oncologists, driving ArteraAI Prostate test adoption.
- FDA clearance for ArteraAI Breast in 2026 validates MMAI platform expansion beyond prostate.
- $65M investment and $100M CARR milestone signal strong commercial traction.
What critics are saying
- Tempus exclusivity enables pricing pressure and volume diversion to its AI tools within 12 months.
- Paige.AI's FDA-cleared prostate AI steals pathology lab contracts from Artera in 6 months.
- Decipher and Oncotype DX dominate NCCN guidelines, undercutting Artera reimbursement in 12 months.
What makes ArteraAI unique
- ArteraAI Prostate Test uniquely predicts hormone therapy benefit and prognosticates outcomes using MMAI on biopsy images.
- First AI test included in 2024 NCCN Guidelines with Level IB evidence from Phase 3 trials.
- FDA Breakthrough Designation for ArteraAI Prostate on July 9, 2025, accelerates approval.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions. Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help identify which patients with biochemical recurrence following radical prostatectomy may benefit from intensified salvage therapy.[1] Specifically, the multimodal artificial intelligence (MMAI) test provides prognostic insight into the potential benefit of adding short-term androgen deprivation therapy (ADT) to radiation. In an interview with Urology Times(R), Daniel Spratt, MD, a radiation oncologist at University Hospitals Seidman Cancer Center in Cleveland, Ohio, discussed the clinical challenges of managing biochemical recurrence and how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. According to Spratt, clinicians have long lacked a reliable tool to support decision-making in this setting - a gap the ArteraAI Prostate Test was developed to address. Spratt explained, "This [test] uses [patients'] clinical and pathologic features as well as, very importantly, digital pathology, running an artificial intelligence algorithm to help us put all these features together to identify patients at low risk of developing recurrence and metastatic disease vs those patients at much higher risk." "When you use this MMAI test, it's really profound. Those with a low MMAI score have a much lower risk of developing recurrence or metastatic disease. So, the benefit of hormone therapy is only a couple percent. It's not zero, but it's a much smaller benefit vs when you find a patient who has a high MMAI score, [where] you're talking about benefits of 20% or higher in terms of reductions in metastatic disease," said Spratt. 1. Artera debuts ArteraAI Prostate Test (Post-RP), expanding its oncology portfolio. News release. Artera. December 9, 2025. Accessed January 1, 2025. 2. New data validating the first AI-based biomarker to stratify risk of metastasis in radical prostatectomy patients with biochemical recurrence. News release. Artera. May 6, 2024. Accessed January 1, 2025. Stay current with the latest urology news and practice-changing insights - sign up now for the essential updates every urologist needs.
Artera announces a $65M growth investment and a major milestone of reaching $100 million in Contracted Annual Recurring Revenue (CARR)..
Sept. 26, 2025 - Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO) in San Francisco, Calif..
Artera presenting validation data at 2025 ASCO Annual Meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care.
AI Study Challenges Fears of Racial Bias in Prostate Cancer Care. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Informatics. – The study rigorously assessed Artera’s MMAI model and confirmed its ability to perform similarly across different racial subgroups using data from diverse prostate cancer clinical trials.Addressing the Challenge of AI Racial Bias in OncologyThis research comes at a crucial time as AI tools are increasingly integrated into clinical decision-making. However, valid concerns persist that these technologies could inadvertently worsen healthcare inequities due to racial bias, particularly if developed using datasets not representative of real-world patient populations. This is a pronounced concern in prostate cancer, where African American men have historically faced a worse prognosis, partly attributed to their underrepresentation in the development of AI tools and genomic biomarkers. Many current AI models have been trained on datasets that lack diversity, raising questions about their applicability and fairness across all patient groups